Jason Aldred is a Neurology physician affiliated with Inland Northwest Health Services. OpenAlex indexes 85 publications with 2,109 citations (h-index 20).
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
610 S Sherman St
Suite 201
Spokane, WA 992021342
Telephone
509-458-7720Registry record last updated 5 Jun 2014.
Industry payments
32 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Teva Pharmaceuticals USA, Inc.Program year202581 payments$115,214openpaymentsdata.cms.gov ↗
- ABBVIE INC.Program year202553 payments$78,090openpaymentsdata.cms.gov ↗
- Amneal Pharmaceuticals LLCProgram year202513 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Musculoskeletal
92.5%Neuromuscular Blocker89.9%Incobotulinumtoxin a77%Abobotulinumtoxina16%Onabotulinumtoxina8%Part B, office-administered≥68 patientsAcetylcholine Release Inhibitor2.5%Rimabotulinumtoxinb100%Part B, office-administered≥18 patients+ 1 more class in this area
Nervous system
7.2%Aromatic Amino Acid Decarboxylation Inhibitor2.9%Carbidopa-Levodopa51%Carbidopa-Levodopa Er35%Rytary12%Crexont1%Carbidopa-Levodopa-Entacapone1%Part D<11 patientsBenzodiazepine0.5%Clonazepam80%Diazepam11%Lorazepam10%Part D<11 patients+ 22 more classes in this area
Cardiovascular
0.1%Beta blocker0.1%Propranolol Hcl Er100%Part D≥17 patientsalpha-Adrenergic Agonist0%Midodrine Hcl100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Efficacy and Safety of Foslevodopa/Foscarbidopa Monotherapy in Patients with Parkinson's Disease
Movement Disorders Clinical Practice
2025 - Sustained Therapeutic Benefits Using Image‐Guided Programming at Activation of Deep Brain Stimulation for Parkinson's Disease
Movement Disorders Clinical Practice
2025 - Treatment patterns with long-term foslevodopa/foscarbidopa use in Parkinson’s disease
Parkinsonism & Related Disorders
2025
Similar KOLs
Other experts from the same institution or the same specialty.
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”